Stem Cell Reviews and Reports

, Volume 10, Issue 3, pp 327–337 | Cite as

Pluripotent Stem Cells as a Potential Tool for Disease Modelling and Cell Therapy in Diabetes

  • Essam M. AbdelalimEmail author
  • Amélie Bonnefond
  • Annelise Bennaceur-Griscelli
  • Philippe FroguelEmail author


Diabetes mellitus is the most prevailing disease with progressive incidence worldwide. To date, the pathogenesis of diabetes is far to be understood, and there is no permanent treatment available for diabetes. One of the promising approaches to understand and cure diabetes is to use pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced PCSs (iPSCs). ESCs and iPSCs have a great potential to differentiate into all cell types, and they have a high ability to differentiate into insulin-secreting β cells. Obtaining PSCs genetically identical to the patient presenting with diabetes has been a longstanding dream for the in vitro modeling of disease and ultimately cell therapy. For several years, somatic cell nuclear transfer (SCNT) was the method of choice to generate patient-specific ESC lines. However, this technology faces ethical and practical concerns. Interestingly, the recently established iPSC technology overcomes the major problems of other stem cell types including the lack of ethical concern and no risk of immune rejection. Several iPSC lines have been recently generated from patients with different types of diabetes, and most of these cell lines are able to differentiate into insulin-secreting β cells. In this review, we summarize recent advances in the differentiation of pancreatic β cells from PSCs, and describe the challenges for their clinical use in diabetes cell therapy. Furthermore, we discuss the potential use of patient-specific PSCs as an in vitro model, providing new insights into the pathophysiology of diabetes.


Diabetes mellitus Embryonic stem cells (ESCs) Induced pluripotent stem cells (iPSCs) Insulin-secreting cells Pancreatic β cells Cell therapy 


Conflict of Interest Statement

We declare no potential conflicts of interest


  1. 1.
    Thomson, J. A., et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282(5391), 1145–1147.PubMedCrossRefGoogle Scholar
  2. 2.
    Takahashi, K., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861–872.PubMedCrossRefGoogle Scholar
  3. 3.
    Aoi, T., et al. (2008). Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science, 321(5889), 699–702.PubMedCrossRefGoogle Scholar
  4. 4.
    Hanna, J., et al. (2008). Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell, 133(2), 250–264.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Yu, J., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318(5858), 1917–1920.PubMedCrossRefGoogle Scholar
  6. 6.
    Abdelalim, E. M. (2013). Molecular mechanisms controlling the cell cycle in embryonic stem cells. Stem Cell Reviews, 9(6), 764–773.PubMedCrossRefGoogle Scholar
  7. 7.
    Ruiz, S., et al. (2011). A high proliferation rate is required for cell reprogramming and maintenance of human embryonic stem cell identity. Current Biology, 21(1), 45–52.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Zhang, Z. N., et al. (2013). Oct4 maintains the pluripotency of human embryonic stem cells by inactivating p53 through Sirt1-mediated deacetylation. Stem Cells, 32, 157–65.CrossRefGoogle Scholar
  9. 9.
    Chin, M. H., et al. (2009). Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell, 5(1), 111–123.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Stadtfeld, M., et al. (2008). Induced pluripotent stem cells generated without viral integration. Science, 322(5903), 945–949.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Danaei, G., et al. (2011). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet, 378(9785), 31–40.PubMedCrossRefGoogle Scholar
  12. 12.
    Gregg, E. W., et al. (2007). Mortality trends in men and women with diabetes, 1971 to 2000. Annals of Internal Medicine, 147(3), 149–155.PubMedCrossRefGoogle Scholar
  13. 13.
    Tisch, R., & McDevitt, H. (1996). Insulin-dependent diabetes mellitus. Cell, 85(3), 291–297.PubMedCrossRefGoogle Scholar
  14. 14.
    van Belle, T. L., Coppieters, K. T., & von Herrath, M. G. (2011). Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiological Reviews, 91(1), 79–118.PubMedCrossRefGoogle Scholar
  15. 15.
    Doria, A., Patti, M. E., & Kahn, C. R. (2008). The emerging genetic architecture of type 2 diabetes. Cell Metabolism, 8(3), 186–200.PubMedCrossRefGoogle Scholar
  16. 16.
    Bonnefond, A., Froguel, P., & Vaxillaire, M. (2010). The emerging genetics of type 2 diabetes. Trends in Molecular Medicine, 16(9), 407–416.PubMedCrossRefGoogle Scholar
  17. 17.
    Vaxillaire, M., & Froguel, P. (2008). Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes. Endocrine Reviews, 29(3), 254–264.PubMedCrossRefGoogle Scholar
  18. 18.
    Bonnefond, A., et al. (2012). Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene. PLoS One, 7(6), e37423.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Efrat, S. (2008). Beta-cell replacement for insulin-dependent diabetes mellitus. Advanced Drug Delivery Reviews, 60(2), 114–123.PubMedCrossRefGoogle Scholar
  20. 20.
    Maehr, R., et al. (2009). Generation of pluripotent stem cells from patients with type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 106(37), 15768–15773.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Tateishi, K., et al. (2008). Generation of insulin-secreting islet-like clusters from human skin fibroblasts. Journal of Biological Chemistry, 283(46), 31601–31607.PubMedCrossRefGoogle Scholar
  22. 22.
    Zhang, D., et al. (2009). Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Research, 19(4), 429–438.PubMedCrossRefGoogle Scholar
  23. 23.
    Jiang, J., et al. (2007). Generation of insulin-producing islet-like clusters from human embryonic stem cells. Stem Cells, 25(8), 1940–1953.PubMedCrossRefGoogle Scholar
  24. 24.
    Chen, S., et al. (2009). A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nature Chemical Biology, 5(4), 258–265.PubMedCrossRefGoogle Scholar
  25. 25.
    Kroon, E., et al. (2008). Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nature Biotechnology, 26(4), 443–452.PubMedCrossRefGoogle Scholar
  26. 26.
    D’Amour, K. A., et al. (2006). Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nature Biotechnology, 24(11), 1392–1401.PubMedCrossRefGoogle Scholar
  27. 27.
    Lumelsky, N., et al. (2001). Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science, 292(5520), 1389–1394.PubMedCrossRefGoogle Scholar
  28. 28.
    Thatava, T., et al. (2011). Indolactam V/GLP-1-mediated differentiation of human iPS cells into glucose-responsive insulin-secreting progeny. Gene Therapy, 18(3), 283–293.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Kunisada, Y., et al. (2012). Small molecules induce efficient differentiation into insulin-producing cells from human induced pluripotent stem cells. Stem Cell Research, 8(2), 274–284.PubMedCrossRefGoogle Scholar
  30. 30.
    Nostro, M. C., et al. (2011). Stage-specific signaling through TGFbeta family members and WNT regulates patterning and pancreatic specification of human pluripotent stem cells. Development, 138(5), 861–871.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Shim, J. H., et al. (2007). Directed differentiation of human embryonic stem cells towards a pancreatic cell fate. Diabetologia, 50(6), 1228–1238.PubMedCrossRefGoogle Scholar
  32. 32.
    Gage, B. K., Webber, T. D., & Kieffer, T. J. (2013). Initial cell seeding density influences pancreatic endocrine development during in vitro differentiation of human embryonic stem cells. PLoS One, 8(12), e82076.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Jiang, W., et al. (2007). In vitro derivation of functional insulin-producing cells from human embryonic stem cells. Cell Research, 17(4), 333–344.PubMedCrossRefGoogle Scholar
  34. 34.
    D’Amour, K. A., et al. (2005). Efficient differentiation of human embryonic stem cells to definitive endoderm. Nature Biotechnology, 23(12), 1534–1541.PubMedCrossRefGoogle Scholar
  35. 35.
    Mfopou, J. K., et al. (2010). Noggin, retinoids, and fibroblast growth factor regulate hepatic or pancreatic fate of human embryonic stem cells. Gastroenterology, 138(7), 2233–2245. 2245 e1–14.PubMedCrossRefGoogle Scholar
  36. 36.
    Johannesson, M., et al. (2009). FGF4 and retinoic acid direct differentiation of hESCs into PDX1-expressing foregut endoderm in a time- and concentration-dependent manner. PLoS One, 4(3), e4794.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    McLean, A. B., et al. (2007). Activin a efficiently specifies definitive endoderm from human embryonic stem cells only when phosphatidylinositol 3-kinase signaling is suppressed. Stem Cells, 25(1), 29–38.PubMedCrossRefGoogle Scholar
  38. 38.
    Tian, T., & Meng, A. M. (2006). Nodal signals pattern vertebrate embryos. Cellular and Molecular Life Sciences, 63(6), 672–685.PubMedCrossRefGoogle Scholar
  39. 39.
    Kubo, A., et al. (2004). Development of definitive endoderm from embryonic stem cells in culture. Development, 131(7), 1651–1662.PubMedCrossRefGoogle Scholar
  40. 40.
    Hosoya, M. (2012). Preparation of pancreatic beta-cells from human iPS cells with small molecules. Islets, 4(3), 249–252.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Bruin, J. E., et al. (2013). Characterization of polyhormonal insulin-producing cells derived in vitro from human embryonic stem cells. Stem Cell Research, 12(1), 194–208.PubMedCrossRefGoogle Scholar
  42. 42.
    Bone, H. K., et al. (2011). A novel chemically directed route for the generation of definitive endoderm from human embryonic stem cells based on inhibition of GSK-3. Journal of Cell Science, 124(Pt 12), 1992–2000.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Borowiak, M., et al. (2009). Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. Cell Stem Cell, 4(4), 348–358.PubMedCrossRefGoogle Scholar
  44. 44.
    Wandzioch, E., & Zaret, K. S. (2009). Dynamic signaling network for the specification of embryonic pancreas and liver progenitors. Science, 324(5935), 1707–1710.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Bernardo, A. S., et al. (2009). Biphasic induction of Pdx1 in mouse and human embryonic stem cells can mimic development of pancreatic beta-cells. Stem Cells, 27(2), 341–351.PubMedCrossRefGoogle Scholar
  46. 46.
    Zhu, F. F., et al. (2011). Generation of pancreatic insulin-producing cells from rhesus monkey induced pluripotent stem cells. Diabetologia, 54(9), 2325–2336.PubMedCrossRefGoogle Scholar
  47. 47.
    Sakano, D., et al. (2014). VMAT2 identified as a regulator of late-stage beta-cell differentiation. Nat Chem Biol, 10, 141–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Ohmine, S., et al. (2012). Reprogrammed keratinocytes from elderly type 2 diabetes patients suppress senescence genes to acquire induced pluripotency. Aging (Albany NY), 4(1), 60–73.Google Scholar
  49. 49.
    Rezania, A., et al. (2013). Enrichment of human embryonic stem cell-derived NKX6.1-expressing pancreatic progenitor cells accelerates the maturation of insulin-secreting cells in vivo. Stem Cells, 31, 2432–2442.PubMedCrossRefGoogle Scholar
  50. 50.
    Blyszczuk, P., et al. (2003). Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin-producing cells. Proceedings of the National Academy of Sciences of the United States of America, 100(3), 998–1003.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Kwon, Y. D., et al. (2005). Cellular manipulation of human embryonic stem cells by TAT-PDX1 protein transduction. Molecular Therapy, 12(1), 28–32.PubMedCrossRefGoogle Scholar
  52. 52.
    Soria, B., et al. (2000). Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes, 49(2), 157–162.PubMedCrossRefGoogle Scholar
  53. 53.
    Liew, C. G., et al. (2008). PAX4 enhances beta-cell differentiation of human embryonic stem cells. PLoS One, 3(3), e1783.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Hua, H., et al. (2013). iPSC-derived beta cells model diabetes due to glucokinase deficiency. Journal of Clinical Investigation, 123(7), 3146–3153.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Thatava, T., et al. (2013). Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells. Molecular Therapy, 21(1), 228–239.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Teo, A. K., Wagers, A. J., & Kulkarni, R. N. (2013). New opportunities: harnessing induced pluripotency for discovery in diabetes and metabolism. Cell Metabolism, 18(6), 775–791.PubMedCrossRefGoogle Scholar
  57. 57.
    Kelly, O. G., et al. (2011). Cell-surface markers for the isolation of pancreatic cell types derived from human embryonic stem cells. Nature Biotechnology, 29(8), 750–756.PubMedCrossRefGoogle Scholar
  58. 58.
    Cai, J., et al. (2010). Generation of homogeneous PDX1(+) pancreatic progenitors from human ES cell-derived endoderm cells. Journal of Molecular Cell Biology, 2(1), 50–60.PubMedCrossRefGoogle Scholar
  59. 59.
    Xu, X., Browning, V. L., & Odorico, J. S. (2011). Activin, BMP and FGF pathways cooperate to promote endoderm and pancreatic lineage cell differentiation from human embryonic stem cells. Mechanisms of Development, 128(7–10), 412–427.PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Rezania, A., et al. (2012). Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice. Diabetes, 61(8), 2016–2029.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Bruin, J. E., et al. (2013). Maturation and function of human embryonic stem cell-derived pancreatic progenitors in macroencapsulation devices following transplant into mice. Diabetologia, 56(9), 1987–1998.PubMedCrossRefGoogle Scholar
  62. 62.
    Alipio, Z., et al. (2010). Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic beta-like cells. Proceedings of the National Academy of Sciences of the United States of America, 107(30), 13426–13431.PubMedCentralPubMedCrossRefGoogle Scholar
  63. 63.
    Jeon, K., et al. (2012). Differentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model. Stem Cells and Development, 21(14), 2642–2655.PubMedCentralPubMedCrossRefGoogle Scholar
  64. 64.
    Yang, X., et al. (2007). Nuclear reprogramming of cloned embryos and its implications for therapeutic cloning. Nature Genetics, 39(3), 295–302.PubMedCrossRefGoogle Scholar
  65. 65.
    Lanza, R. P., Cibelli, J. B., & West, M. D. (1999). Prospects for the use of nuclear transfer in human transplantation. Nature Biotechnology, 17(12), 1171–1174.PubMedCrossRefGoogle Scholar
  66. 66.
    Wilmut, I., et al. (1997). Viable offspring derived from fetal and adult mammalian cells. Nature, 385(6619), 810–813.PubMedCrossRefGoogle Scholar
  67. 67.
    Tachibana, M., et al. (2013). Human embryonic stem cells derived by somatic cell nuclear transfer. Cell, 153(6), 1228–1238.PubMedCrossRefGoogle Scholar
  68. 68.
    Araki, R., et al. (2013). Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature, 494(7435), 100–104.PubMedCrossRefGoogle Scholar
  69. 69.
    Sermon, K. D., et al. (2009). Creation of a registry for human embryonic stem cells carrying an inherited defect: joint collaboration between ESHRE and hESCreg. Human Reproduction, 24(7), 1556–1560.PubMedCrossRefGoogle Scholar
  70. 70.
    Verlinsky, Y., et al. (2005). Human embryonic stem cell lines with genetic disorders. Reproductive Biomedicine Online, 10(1), 105–110.PubMedCrossRefGoogle Scholar
  71. 71.
    Eiges, R., et al. (2007). Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell, 1(5), 568–577.PubMedCrossRefGoogle Scholar
  72. 72.
    Mateizel, I., et al. (2006). Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. Human Reproduction, 21(2), 503–511.PubMedCrossRefGoogle Scholar
  73. 73.
    Lee, G., & Studer, L. (2010). Induced pluripotent stem cell technology for the study of human disease. Nature Methods, 7(1), 25–27.PubMedCrossRefGoogle Scholar
  74. 74.
    Maehr, R. (2011). iPS cells in type 1 diabetes research and treatment. Clinical Pharmacology and Therapeutics, 89(5), 750–753.PubMedCrossRefGoogle Scholar
  75. 75.
    Teo, A. K., et al. (2013). Derivation of human induced pluripotent stem cells from patients with maturity onset diabetes of the young. Journal of Biological Chemistry, 288(8), 5353–5356.PubMedCentralPubMedCrossRefGoogle Scholar
  76. 76.
    Kudva, Y. C., et al. (2012). Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. Stem Cells Translational Medicine, 1(6), 451–461.PubMedCentralPubMedCrossRefGoogle Scholar
  77. 77.
    Velho, G., et al. (1992). Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young. Lancet, 340(8817), 444–448.PubMedCrossRefGoogle Scholar
  78. 78.
    Estalella, I., et al. (2007). Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain. Clinical Endocrinology, 67(4), 538–546.PubMedGoogle Scholar
  79. 79.
    Froguel, P., et al. (1993). Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. New England Journal of Medicine, 328(10), 697–702.PubMedCrossRefGoogle Scholar
  80. 80.
    Byrne, M. M., et al. (1994). Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. Journal of Clinical Investigation, 93(3), 1120–1130.PubMedCentralPubMedCrossRefGoogle Scholar
  81. 81.
    Li, H., et al. (2009). The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature, 460(7259), 1136–1139.PubMedCentralPubMedCrossRefGoogle Scholar
  82. 82.
    Banito, A., et al. (2009). Senescence impairs successful reprogramming to pluripotent stem cells. Genes and Development, 23(18), 2134–2139.PubMedCentralPubMedCrossRefGoogle Scholar
  83. 83.
    Hanna, J., et al. (2009). Metastable pluripotent states in NOD-mouse-derived ESCs. Cell Stem Cell, 4(6), 513–524.PubMedCentralPubMedCrossRefGoogle Scholar
  84. 84.
    Okita, K., Ichisaka, T., & Yamanaka, S. (2007). Generation of germline-competent induced pluripotent stem cells. Nature, 448(7151), 313–317.PubMedCrossRefGoogle Scholar
  85. 85.
    Okita, K., et al. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. Science, 322(5903), 949–953.PubMedCrossRefGoogle Scholar
  86. 86.
    Soldner, F., et al. (2009). Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell, 136(5), 964–977.PubMedCentralPubMedCrossRefGoogle Scholar
  87. 87.
    Kaji, K., et al. (2009). Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature, 458(7239), 771–775.PubMedCentralPubMedCrossRefGoogle Scholar
  88. 88.
    Woltjen, K., et al. (2009). piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature, 458(7239), 766–770.PubMedCentralPubMedCrossRefGoogle Scholar
  89. 89.
    Zhou, H., et al. (2009). Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell, 4(5), 381–384.PubMedCrossRefGoogle Scholar
  90. 90.
    Kim, D., et al. (2009). Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell, 4(6), 472–476.PubMedCentralPubMedCrossRefGoogle Scholar
  91. 91.
    Yamanaka, S. (2007). Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell, 1(1), 39–49.PubMedCrossRefGoogle Scholar
  92. 92.
    Knoepfler, P. S. (2008). Why myc? An unexpected ingredient in the stem cell cocktail. Cell Stem Cell, 2(1), 18–21.PubMedCrossRefGoogle Scholar
  93. 93.
    Nakagawa, M., et al. (2008). Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nature Biotechnology, 26(1), 101–106.PubMedCrossRefGoogle Scholar
  94. 94.
    Wernig, M., et al. (2008). c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell, 2(1), 10–12.PubMedCrossRefGoogle Scholar
  95. 95.
    Obokata, H., et al. (2014). Stimulus-triggered fate conversion of somatic cells into pluripotency. Nature, 505(7485), 641–647.PubMedCrossRefGoogle Scholar
  96. 96.
    Obokata, H., et al. (2014). Bidirectional developmental potential in reprogrammed cells with acquired pluripotency. Nature, 505(7485), 676–680.PubMedCrossRefGoogle Scholar
  97. 97.
    Santana, A., et al. (2006). Insulin-producing cells derived from stem cells: recent progress and future directions. Journal of Cellular and Molecular Medicine, 10(4), 866–883.PubMedCrossRefGoogle Scholar
  98. 98.
    Shapiro, A. M., et al. (2000). Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. New England Journal of Medicine, 343(4), 230–238.PubMedCrossRefGoogle Scholar
  99. 99.
    Penfornis, A., & Kury-Paulin, S. (2006). Immunosuppressive drug-induced diabetes. Diabetes & Metabolism, 32(5 Pt 2), 539–546.CrossRefGoogle Scholar
  100. 100.
    Fiorina, P., Voltarelli, J., & Zavazava, N. (2011). Immunological applications of stem cells in type 1 diabetes. Endocrine Reviews, 32(6), 725–754.PubMedCentralPubMedCrossRefGoogle Scholar
  101. 101.
    Patterson, M., et al. (2012). Defining the nature of human pluripotent stem cell progeny. Cell Research, 22(1), 178–193.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Essam M. Abdelalim
    • 1
    • 2
    Email author
  • Amélie Bonnefond
    • 1
    • 3
    • 4
    • 5
  • Annelise Bennaceur-Griscelli
    • 6
    • 7
  • Philippe Froguel
    • 1
    • 3
    • 4
    • 5
    • 8
    Email author
  1. 1.Qatar Biomedical Research InstituteQatar FoundationDohaQatar
  2. 2.Department of Cytology and Histology, Faculty of Veterinary MedicineSuez Canal UniversityIsmailiaEgypt
  3. 3.CNRS UMR8199Pasteur Institute of LilleLilleFrance
  4. 4.Lille 2 UniversityLilleFrance
  5. 5.European Genomic Institute for Diabetes (EGID)LilleFrance
  6. 6.INSERM UMR S935, ESTeam Paris SudUniversité Paris Sud 11VillejuifFrance
  7. 7.AP-HP Laboratory of HematologyCHUBicêtreFrance
  8. 8.Department of Genomics of Common Disease, Hammersmith HospitalImperial College LondonLondonUK

Personalised recommendations